<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; recasting</title>
	<atom:link href="http://www.tapanray.in/tag/recasting/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Rebalance KOL-Mix As Covid-19 Redefines Pharma Marketing</title>
		<link>http://www.tapanray.in/rebalance-kol-mix-as-covid-19-redefines-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=rebalance-kol-mix-as-covid-19-redefines-pharma-marketing</link>
		<comments>http://www.tapanray.in/rebalance-kol-mix-as-covid-19-redefines-pharma-marketing/#comments</comments>
		<pubDate>Mon, 24 May 2021 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[axioms]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[enablement]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[influencers]]></category>
		<category><![CDATA[KOL]]></category>
		<category><![CDATA[KOL-mix]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[outreach]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Rebalancing]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[redefined]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[tech-stack]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10511</guid>
		<description><![CDATA[‘It’s safe to say that 2020 was a year like no other and that 2021 will certainly not revert back to the old normal,’ reiterated the Harvard Business Review Article - ‘10 Truths About Marketing After the Pandemic,’ of March 10, 2021. Amid &#8230; <a href="http://www.tapanray.in/rebalance-kol-mix-as-covid-19-redefines-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/rebalance-kol-mix-as-covid-19-redefines-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Stakeholder-Mix Has Changed, But Pharma Marketing Has Not</title>
		<link>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-stakeholder-mix-has-changed-but-pharma-marketing-has-not</link>
		<comments>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/#comments</comments>
		<pubDate>Mon, 13 Jun 2016 00:00:25 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[biomarkers]]></category>
		<category><![CDATA[captains]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[inclusive]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[multi-stakeholder]]></category>
		<category><![CDATA[multichannel]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[paradigm]]></category>
		<category><![CDATA[personalized]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[pipeline]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[President]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[recasting]]></category>
		<category><![CDATA[Self]]></category>
		<category><![CDATA[serving]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7670</guid>
		<description><![CDATA[“We try never to forget that medicine is for the people. It is not for profit. Profits follow, and if we have remembered that, they never fail to appear.” In 1952, George Wilhelm Herman Emanuel Merck, the then President of &#8230; <a href="http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-stakeholder-mix-has-changed-but-pharma-marketing-has-not/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
